

February 5, 2026

BSE Limited

Department of Corporate Relationship
1st Floor, New Trade Ring, Rotunda Building
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai- 400001
Scrip Code: 524742

Dear Sir/Madam,

Sub: Outcome of Board Meeting

Further to our intimation dated January 27, 2026, we wish to inform you that the Board of Directors, at its meeting held today i.e. February 5, 2026, has, inter-alia approved the Un-audited standalone and consolidated financial results and the Limited Review Report (**Annexure-1**) of the Company as per Indian Accounting Standards for the quarter and nine months ended December 31, 2025. We also enclose a Press Release issued by the Company (**Annexure 2**) and an investor presentation in this regard (**Annexure 3**).

The meeting commenced at 11.00 A.M and concluded at 1.00 P.M.

Kindly take the same on your records.

Sincerely Yours

For Caplin Point Laboratories Limited

Venkatram G

General Counsel & Company Secretary

Membership No. A23989

Encl: A/a

Independent Auditor's Review Report on Unaudited Standalone Quarterly and Year to Date Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

**The Board of Directors of
Caplin Point Laboratories Limited**

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **Caplin Point Laboratories Limited** ("the Company") for the quarter ended 31st December 2025 and for the period from 1st April 2025 to 31st December 2025 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
2. The Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the Statement prepared in accordance with the applicable Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in

terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Brahmayya & Co.,
Chartered Accountants
Firm Regn No. 000511S



N. Sri Krishna
Partner
Membership No. 026575
UDIN: 26026575VRJXWU5200

Place : Dubai
Date : 5th February 2026

CAPLIN POINT LABORATORIES LIMITED						
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025						
Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
	(1)	(2)	(3)	(4)	(5)	(6)
(Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited)						
₹ In Crores						
Income:						
I Revenue from operations	189.22	175.18	185.23	546.97	578.80	752.41
II Other income	31.73	59.22	28.83	122.99	93.34	134.59
III Total Income (I+II)	220.95	234.40	214.06	669.96	672.14	887.00
IV Expenses:						
a. Cost of materials consumed	39.47	34.92	33.29	113.01	102.39	136.64
b. Purchase of traded goods	23.45	21.21	19.24	57.84	59.78	77.17
c. Changes in inventories of finished goods, stock in trade and work in progress	(5.80)	2.05	8.19	2.52	20.70	24.36
d. Employee benefits expense	13.41	11.54	13.89	34.57	37.74	52.13
e. Finance costs	0.07	0.05	0.04	0.15	0.08	0.12
f. Depreciation & Amortisation Expense	6.37	6.02	6.01	18.53	18.68	24.77
g. Other Expenses	26.97	29.61	33.23	84.83	101.26	130.14
Total Expenses	103.94	105.40	113.89	311.45	340.63	445.33
V Profit before exceptional items and Tax (III-IV)	117.01	129.00	100.17	358.51	331.51	441.67
VI Exceptional items	-	-	-	-	-	-
VI Profit Before Tax (V-VI)	117.01	129.00	100.17	358.51	331.51	441.67
VIII Tax Expenses						
(1) Current Tax	29.35	26.77	25.55	83.04	79.27	102.90
(2) Deferred Tax	0.38	(0.36)	(0.09)	(0.32)	(0.75)	(0.72)
Total Tax Expenses	29.73	26.41	25.46	82.72	78.52	102.18
IX Net Profit for the period (VII-VIII)	87.28	102.59	74.71	275.79	252.99	339.49
X Other Comprehensive Income/ (Loss) -						
Net of Tax						
A. Items that will not be re-classified to profit or loss						
i) Remeasurements of Defined Benefit Plan	(0.58)	0.67	-	0.08	0.16	(0.13)
ii) Income tax relating to these items	0.15	(0.17)	-	(0.02)	(0.04)	0.03
XI Total Comprehensive Income For The Period (IX+X)	86.85	103.09	74.71	275.85	253.11	339.39
XII Paid up Equity Share Capital (Face value of shares of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	15.20
XIII Other equity						1,685.73
XIV Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*						
(a) Basic (in Rupees)	11.49	13.50	9.83	36.28	33.30	44.67
(b) Diluted (in Rupees)	11.46	13.45	9.77	36.17	33.12	44.47
	(Not Annualised)	(Annualised)				

See Accompanying notes to Financial Results

* BRAHMAYYA & CO.
CHARTERED ACCOUNTANTS
For Identification Only



CAPLIN POINT LABORATORIES LIMITED

Standalone Notes:

- 1) The above Standalone financial Results for the quarter and Nine Months ended December 31, 2025 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 5, 2026 and reviewed by the Statutory Auditors.
- 2) The Unaudited Standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Company is engaged in the sole activity of carrying on the business of "Pharmaceutical Formulations" and therefore no separate segment reporting is applicable to the Company.
- 4) Other Income and Profit Before Tax includes:

Particulars	₹ In Crores					
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
Dividend from wholly owned subsidiary Caplin Point Far East Limited	-	23.63	-	31.75	20.40	35.53

- 5) During the quarter and Nine Months ended December 31, 2025, the Company has allotted NIL equity shares of ₹2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as of December 31, 2025, and 7,60,11,696 as of December 31, 2024. The Company had allotted NIL shares and 69,950 shares during the quarter ended and Nine Month ended December 31, 2024, respectively.
- 6) Pursuant to the notification of the New Labour Codes effective 21st November, 2025 by Government of India whereby multiple existing labour legislations have been consolidated into a unified framework, the Company has assessed the implications of the revised definition of "wages" for employees. The assessment has resulted in an increase in gratuity and compensated absence related employee benefit obligations aggregating to ₹0.84 Crores and the impact of the same has been taken in the current quarter results.

The Company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with applicable accounting standards.

- 7) Previous periods' figures have been regrouped / reclassified to be in conformity with current period's classification / disclosure, wherever necessary.



For and on behalf of the Board

Dr. Sridhar Ganesan
Managing Director

Place: Chennai
Date: February 5, 2026



Independent Auditor's Review Report on Unaudited Consolidated Quarterly and Year to Date Financial Results of Caplin Point Laboratories Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

**The Board of Directors of
Caplin Point Laboratories Limited**

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of **Caplin Point Laboratories Limited** ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") and its share of net profit / (loss) after tax and total comprehensive income / loss of associate for the quarter ended 31st December 2025 and for the period from 1st April 2025 to 31st December 2025 ("the Statement") being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'), to the extent applicable.
2. This Statement, which is the responsibility of the Holding Company's management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India ("ICAI"). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes results of the following entities:

Subsidiary Companies

Name of the Entity	Relationship
Caplin Steriles Limited, India	Subsidiary
Argus Salud Pharma LLP, India	Subsidiary
Caplin One Labs Limited, India (Formerly known as Caplin Onco Limited)	Wholly owned subsidiary
Caplin Point Far East Limited, Hong Kong	Wholly owned subsidiary
Caplin Point (S) Pte. Ltd, Singapore	Wholly owned subsidiary

Step Down Subsidiaries (Subsidiaries of Caplin Point Far East Limited, Hong Kong)

Name of the Entity	Relationship
Caplin Point EL Salvador, S.A. DE C.V., El Salvador	Step Down Subsidiary
Nuevos Eticos Neo Ethicals S.A, Guatemala	Step Down Subsidiary
Neoethicals CIA.LTDA, Ecuador	Step Down Subsidiary
Drogueria Saimed de Honduras S.A., Honduras	Step Down Subsidiary
Neo Ethicals S.A, Nicaragua	Step Down Subsidiary
Caplin Point Laboratories Colombia SAS, Colombia	Step Down Subsidiary
Neoethicals Chile SpA, Chile	Step Down Subsidiary
Triwin Pharma S.A DE C.V Mexico, Mexico	Step Down Subsidiary

Step Down Subsidiary (Subsidiary of Caplin Steriles Limited, India)

Name of the Entity	Relationship
Caplin Steriles USA Inc., USA	Step Down Subsidiary

Associate Company of Caplin Steriles Limited

Name of the Entity	Relationship
Sunsole Solar Private Limited, India	Associate

- Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
- We did not review the interim results of five subsidiaries and seven step-down subsidiaries, whose interim financial results reflect total revenues of INR 447.90 crores and INR 1326.97 crores, net profit after tax of INR 71.91 crores and INR 203.53 crores, and total comprehensive income of INR 54.60 Crores and INR 139.67 Crores for the quarter ended on 31st December 2025 and for the period 1st April 2025 to 31st December 2025 respectively, as considered in the Statement. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in Paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

- The Statement includes the interim financial results of two step-down subsidiaries which have not been reviewed by their auditors, whose interim financial results reflect total revenues of INR 26.76 crores and INR 63.07 crores, net profit after tax of INR 2.99 crores and INR 9.69 crores and total comprehensive profit of INR 2.41 crores and INR 9.34 crores for the quarter ended 31st December 2025 and for the period from 1st April 2025 to 31st December 2025 respectively, as considered in the Statement. The Statement also includes the share of net profit / (loss) after tax of INR (0.02) crores and INR 0.04 crores, and total comprehensive income/(loss) of INR (0.02) crores and INR 0.04 crores for the quarter ended 31st December, 2025 and for the period 1st April 2025 to 31st December 2025 as considered in the Statement, in respect of an associate, based on their interim financial results, which has not been reviewed by their auditor. According to the information and

explanations given to us by the management, these interim financial results are not material to the Group.

Our conclusion on the Statement is not modified in respect of this matter.

For Brahmayya & Co.,
Chartered Accountants
Firm Regn No. 000511S



N. Sri Krishna
Partner
Membership No. 026575
UDIN: 26026575QXCZBM1232

Place : Dubai
Date : 5th February 2026

CAPLIN POINT LABORATORIES LIMITED							
STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025							
Particulars	Quarter Ended			Nine Months Ended		Year Ended	
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025	
	(1)	(2)	(3)	(4)	(5)	(6)	
(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
	₹ in Crores						
Income:							
I Revenue from operations	542.77	534.04	492.96	1,587.03	1,435.02	1,937.47	
II Other income	33.68	30.37	31.36	87.18	70.69	96.43	
III Total Income (I+II)	576.45	564.41	524.32	1,674.21	1,505.71	2,033.90	
IV Expenses:							
a. Cost of materials consumed	89.24	92.34	59.80	255.09	187.61	248.45	
b. Purchase of traded goods	128.00	121.68	139.43	363.18	436.93	483.83	
c. Changes in inventories of finished goods, stock in trade and work in progress	(2.10)	(3.72)	(3.88)	2.41	(54.90)	38.56	
d. Employee benefits expense	49.78	47.23	46.77	140.18	131.21	177.72	
e. Finance costs	0.18	0.16	0.18	0.51	0.44	0.61	
f. Depreciation & Amortisation Expense	19.28	18.40	16.20	53.97	48.92	65.96	
g. Other Expenses	88.16	87.34	88.55	269.56	255.31	341.98	
Total Expenses	372.54	363.43	347.05	1,084.90	1,005.51	1,357.11	
V Profit before share of profit in Associate, Exceptional Items and tax (III-IV)	203.91	200.98	177.27	589.31	500.20	676.79	
VI Share of Profit/(Loss) in Associate	(0.02)	0.02	(0.01)	0.04	(0.09)	(0.01)	
VII Exceptional items	-	-	-	-	-	-	
VIII Profit Before Tax (V+VI+VII)	203.89	201.00	177.26	589.35	500.11	676.78	
IX Tax Expenses							
(1) Current Tax	35.64	36.53	34.22	105.27	96.06	125.33	
(2) Deferred Tax	2.39	4.24	2.97	7.23	8.24	10.36	
Total Tax Expenses	38.03	40.77	37.19	112.50	104.30	135.69	
X Net Profit for the period (VIII - IX)	165.86	160.23	140.07	476.85	395.81	541.09	
XI Other Comprehensive Income - Net of Tax							
A. Items that will not be re-classified to profit or loss							
i) Remeasurements of Defined Benefit Plan	(0.95)	1.34	0.04	0.39	0.42	0.14	
ii) Income tax relating to these items	0.24	(0.34)	(0.02)	(0.10)	(0.11)	(0.04)	
B. Items that will be re-classified to profit or loss							
i) Exchange difference in translating the financial statements of foreign operations	17.55	46.54	22.79	64.45	28.51	26.97	
XII Total Comprehensive Income For The Period (X + XI)	182.70	207.77	162.88	541.59	424.63	568.16	
XIII Profit attributable to:							
Owners of the Company	163.88	154.45	138.96	471.13	393.74	536.31	
Non- controlling interests	1.98	5.78	1.11	5.72	2.07	4.78	
	165.86	160.23	140.07	476.85	395.81	541.09	
XIV Total Comprehensive Income For The Period attributable to							
Owners of the Company	180.72	201.99	161.77	535.87	422.56	563.38	
Non- controlling interests	1.98	5.78	1.11	5.72	2.07	4.78	
	182.70	207.77	162.88	541.59	424.63	568.16	
XV Paid up Equity Share Capital (Face value of share of Rs 2/- each)	15.20	15.20	15.20	15.20	15.20	15.20	
XVI Other equity excluding Non-controlling interest							2,835.29
XVII Earnings Per Share (EPS) of Face value Rs 2/- per Equity share*							
(a) Basic (in Rupees)	21.56	20.32	18.28	61.98	51.82	70.57	
(b) Diluted (in Rupees)	21.51	20.25	18.19	61.80	51.55	70.25	
	*(Not Annualised)	*(Annualised)					

See Accompanying notes to Financial Results

• BRAHMAYYA &
CHARTERED ACCOUNTANTS •
For Identification Only

POINT LABORATORIES LTD. CHENNAI
600 096.

CAPLIN POINT LABORATORIES LIMITED
Segment Information- Revenues and Results

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2025	30.09.2025	31.12.2024	31.12.2025	31.12.2024	31.03.2025
	(1)	(2)	(3)	(4)	(5)	(6)
	₹ in Crores					
1) Segment revenue (Total Revenue)						
Rest of the World	432.93	427.08	405.14	1,263.54	1,176.85	1,582.96
USA	109.84	106.96	87.82	323.49	258.17	354.51
Unallocated	33.68	30.37	31.36	87.18	70.69	96.43
Total	576.45	564.41	524.32	1,674.21	1,505.71	2,033.90
2) Segment results (PBT)						
Rest of the World	160.30	156.10	140.88	467.87	404.96	540.34
USA	9.91	14.53	5.02	34.29	24.46	40.01
Unallocated	33.68	30.37	31.36	87.18	70.69	96.43
Total	203.89	201.00	177.26	589.35	500.11	676.78
3) Segment Assets						
Rest of the World	1,720.07	1,588.42	1,387.86	1,720.07	1,387.86	1,448.25
USA	617.91	581.33	572.40	617.91	572.40	580.09
Unallocated	1,380.58	1,334.17	1,081.22	1,380.58	1,081.22	1,179.51
Total	3,718.56	3,503.92	3,041.48	3,718.56	3,041.48	3,207.85
4) Segment Liabilities						
Rest of the World	273.05	251.39	246.13	273.05	246.13	268.91
USA	65.55	53.54	55.69	65.55	55.69	53.28
Unallocated	-	-	-	-	-	-
Total	338.60	304.93	301.82	338.60	301.82	322.19



CAPLIN POINT LABORATORIES LIMITED

Consolidated Notes:

- 1) The above Consolidated Financial Results for the quarter and Nine Months ended December 31, 2025, have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors of the Company at their respective meetings held on February 5, 2026, and reviewed by the Statutory Auditors.
- 2) The unaudited Consolidated Financial Results of the Company has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("Ind AS") and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3) The Group has identified two geographical segments as its reportable segments in accordance with Ind AS 108 – Operating Segments. Segment 1: Rest of the World. Segment 2: United States of America (USA). Accordingly, segment reporting has been presented along with the Consolidated results.
- 4) During the quarter and Nine Months ended December 31, 2025, the Company has allotted NIL equity shares of ₹2/- each under the Employees Stock Option Schemes and the total number of equity shares of the Company stands at 7,60,11,696 as of December 31, 2025, and 7,60,11,696 as of December 31, 2024. The Company had allotted NIL shares and 69,950 shares during the quarter ended and Nine Month ended December 31, 2024, respectively.
- 5) Pursuant to the notification of the New Labour Codes effective 21st November, 2025 by Government of India, whereby multiple existing labour legislations have been consolidated into a unified framework, the Group has assessed the implications of the revised definition of "wages" for employees in India. The assessment has resulted in an increase in gratuity and compensated absence related employee benefit obligations aggregating to ₹1.39 Crores and the impact of the same has been taken in the current quarter results.

The Company continues to monitor developments pertaining to the New Labour Codes, and the impact thereof, if any, will be accounted for in accordance with applicable accounting standards.

- 6) Previous periods' figures have been regrouped/reclassified to be in conformity with current period's classification/ disclosure, wherever necessary.

* BRAHMAYYA & CO.
For
Identification
Only
* CHARTERED ACCOUNTANTS * O

For and on behalf of the Board



Dr. Sridhar Ganesan
Managing Director

Place: Chennai
Date: February 5, 2026





9MFY26 Total revenue of ₹1,674 Crores; an increase of 11.2% YoY

Q3FY26 Total Revenue of ₹577 Crores; an increase of 10% QoQ

9MFY26 PAT of ₹477 Crores; an increase of 20.5% YoY

9MFY26 US market revenue of ₹335 Crores, recording 25% growth YoY.

Free Cash Reserves at ₹1,381 Crores; Liquid Assets at ₹2,459 Crores.

Chennai, 5th February 2026: Caplin Point Laboratories Ltd. (“Caplin Point” or the “Company”) (BSE: 524742 | NSE: CAPLIPOINT), a rapidly expanding and fully integrated pharmaceutical company with a leading market position in Latin America, today announced its financial performance for the quarter ended December 31, 2025.

Consolidated Financial Performance for Q3 FY26 & 9MFY26:

₹ in Crores

Particulars	Q3 FY 26	Q3 FY 25	YoY (%)	Q2 FY 26	QoQ (%)	9M FY26	9M FY25	YoY (%)
Revenue from Operation	542.8	493.0	10.1%	534.0	1.6%	1,587.0	1,435.0	10.6%
Total Revenue	576.5	524.3	9.9%	564.4	2.1%	1,674.2	1,505.7	11.2%
Gross Profit	327.6	297.6	10.1%	323.7	1.2%	966.4	865.4	11.7%
Gross Margin %	60.4%	60.4%		60.6%		60.9%	60.3%	
EBITDA	223.4	193.7	15.3%	219.5	1.7%	643.8	549.6	17.1%
EBITDA Margin %	38.7%	36.9%		38.9%		38.5%	36.5%	
Profit Before Tax	203.9	177.3	15.0%	201.0	1.4%	589.4	500.1	17.8%
PBT Margin %	35.4%	33.8%		35.6%		35.2%	33.2%	
Profit after Tax	165.9	140.1	18.4%	160.2	3.5%	476.9	395.8	20.5%
PAT Margin	28.8%	26.7%		28.4%		28.5%	26.3%	

Other Consolidated Financial Highlights for Q3 FY26 & 9MFY26:

- Gross Margin for 9M FY26 is 60.9% vs 60.3% in 9M FY25 and Q3FY26 is 60.4% vs 60.4% in Q3FY25 at sustained levels.
- EBITDA Margin for 9M FY26 is at 38.5% vs 36.5% in 9M FY25 and Q3FY26 is at 38.7% vs 36.9% in Q3FY25.
- Basic EPS increased by 19.6% to ₹61.98 in 9M FY26 compared to ₹51.82 in 9M FY25.
- Cash Flow from Operations in 9M FY26 is ₹368 Crores vs ₹284 Crores in 9M FY25.
- Free Cash Flow is ₹188 Crores (after Capex investment of ₹180 Crores) in 9M FY26 as compared to ₹153 Crores (after capex investment of ₹131 Crores) in 9M FY25.
- Geographical revenue composition between Emerging Markets (Latin America & Africa) and US for 9M FY26 is in the range of 80% and 20% respectively.
- CSL’s Revenue composition demonstrates a balanced mix of Product Supply and Milestone + Profit Share, with the split for 9M FY26 in the range of 80% and 20% respectively.
- As at 31st December 2025, Inventories are at ₹349 Crores - 55% Stock at the warehouses, close to the customer; In Transit 12%; 33% in India. Receivables are at 121 days.

- As at 31st December 2025, Free Cash reserves are at ₹1,381 Crores and Total Liquid Assets at ₹2,459 Crores.

Business Highlights for Q3 FY26:

Emerging Markets:

- Caplin's end-to-end business model in Central and South American markets continues to drive consistent and profitable growth for the company.
- Company has revenue pipeline arising out of new tender orders in Central American markets to the tune of \$25 million.
- Mexico Update – Company has received approvals for 25 products with a pipeline of 100+ products to be filed within the next 18 months, from CPL and CSL's internal pipeline.
- As part of Caplin's continued vision of "Keeping products closer to the Customer", Company has acquired industrial land in Mexico, aimed at setting up a manufacturing and packaging facility. Company plans to build capacities to manufacture "freight heavy" products such as Oral Liquids/Suspensions, Ointments, Creams and Suppositories in this facility.
- Chile Update – Company shows excellent progress with private market sales in Chile through newly established subsidiary/warehouse. Caplin already holds 125+ product licenses in Chile, with several more under review/pipeline. Chile expected to be one of Caplin's Top 5 markets within 24 months.
- Company has filed its own internally developed GLP-1 products in its Central American markets. Company plans to expand GLP-1 range of products to several markets (post patents expiry) by FY'27.
- Company's "China 2.0" strategy of partnering with Companies that have ANDAs/MA's approved in US and EU gathers pace, with its first Biosimilar product filing in Central America. Company has signed partnerships with multiple Chinese companies, granting access to 80+ approved ANDAs/MAs in the US and EU. These products will be extended to Mexico, Colombia and Chile, under Caplin's name.
- Company's Oncology Injectable segment in Kakkalur completes all qualifications in Jan'26, and is expected to go commercial in a few weeks. Company has acquired several ANDAs in Oncology segment from 3rd parties. These products will be submitted for site transfer to COL's site by end of 2026.
- Company's first API unit, to be used predominantly for backward integration, has completed final qualifications and has scaled up 3 critical APIs. Site will go for Regulatory certifications by end of 2026, with a target towards being backward integrated for 60% of all ANDAs in a few years.
- Civil construction completed at Oncology API site in Thervoy, near Chennai. Facility expected to be operational within 9 months and will cater to Company's budding Oncology business for Regulated and Emerging Markets.

US & Regulated Markets:

- Caplin Steriles Limited (CSL) continues to show robust and profitable growth with both B2B and B2C segments contributing consistently. Current split between B2B and B2C segments is 75% & 25%
- Company receives EU GMP renewal certification for its recently concluded audit. Company also completes Saudi FDA audit successfully in Dec'25.
- Caplin Group has acquired multiple ANDAs from 3rd party companies in order to augment its growth and expand offering in the sterile products segment in Regulated markets. Company expects all acquired products to be ready for launch in the US in 12-15 months time.

- Company currently sitting on 55 ANDAs approved in the US (including partners), and several more approvals in Canada, Mexico, South Africa, UAE, Australia etc. Company's order book remains healthy for next few Quarters.
- CSL receives its first Suspension Injectable product approval, within first cycle in the US. This is in addition to its first cycle approval for an Emulsion Injectable and Emulsion Ophthalmic product, highlighting company's excellent track record from R&D and Regulatory standpoints.
- Company expects multiple new product approvals in the form of Suspension Injectables, Injections in Plastic Vials, Ready-To-Use IV Bags in the next few months. As part of Company's original pattern of "growth through Asset Light/Outsourcing model", Company is working with highly compliant CMO's to takeover high volume/price sensitive injectable products, for US, which are currently being manufactured in-house.
- CSL's Line 6, which is a fully automated robotic line for Pre-Filled Syringes and Cartridges, has completed qualifications. Company will file 12 Pre-Filled Syringe products in US and other Regulated markets from this line, in the next 12 months. Company will also file its first GLP-1 products from this line in Canada, Mexico and several other ex-US markets.
- Project work going on at full swing for CSL's Line 7, which will be a Blow-Fill-Seal line. Company's R&D working to fast-track development of 14 products in both Unit Dose Ophthalmic and Inhalation Space, a segment with very limited competition, for Regulated markets.
- With a vision to be a highly compliant facility with the best-in-class automation in place, Company has taken on a "Visual Integration" project that will convert certain legacy equipment and processes into Automated and Real Time monitored systems. This patented project will be rolled out across all Caplin group's plants in the future. The Company has also recently installed 2 new AI-powered Visual Inspection and IV Bags Leak Detection equipment, from Italy and Japan respectively.
- To accommodate the growing requirements in Capacity, Automation and Compliance, project work continues at full swing at the company's COL-II plant. This is a facility that will house 8 Sterile product lines, capable of manufacturing all the products currently being manufactured and developed at CSL, and also include another niche area in the form of Sterile Ophthalmic Ointments. Company expects COL-II to come to start commercial production in early 2027, with at least 5 injectable/ophthalmic lines.
- **Update on Caplin Steriles USA Inc (CSU) - company's own label in the US:**
 - CSU achieves revenue of \$8.7 million from inception till date (around 15 months), with excellent profitability. CSU continues to show robust cashflows within the first year of operations.
 - Company has launched 29 products under its CSU label and targets another 16+ products to be launched in CY2026.
 - CSU maintains excellent track record of supplies through both direct and indirect sales, and CSL expects its front end to become largest "customers within 12 months".
 - Caplin Group plans to establish a separate retail arm in the US, focused on its Ophthalmic products pipeline, Unit Dose Ophthalmics and Inhalations pipeline, in addition to Oral Solid products licensed from recent partnerships with Chinese companies with approved ANDAs.

Commenting on the performance, Mr. C.C. Paarthipan, Chairman said:

Our performance in the third quarter and the first nine months of FY26 reflects far more than financial outcomes - it reflects the quiet compounding of a long-term strategy built on being different from others. We have sustained our strong margins, expanded profitability, and delivered robust cash generation, all while continuing to invest heavily in capacity, technology, people and future platforms. This balance between growth and prudence remains central to how we think about building enduring value.

In Emerging Markets, our end-to-end business model continues to create a powerful competitive moat, as we create enriching value on both sides by catering to the bottom of the pyramid. By keeping products closer to customers, expanding local presence, and broadening our portfolio through internal development and global partnerships, we are steadily deepening relevance in markets that value reliability, affordability, and long-term commitment. Our progress in Latin America, the scaling of GLP-1 products, the acceleration of our “China 2.0” strategy, and our investments in oncology and APIs reinforce our belief that resilience is built through thoughtful vertical integration and geographic diversification.

In the US and other regulated markets, Caplin Steriles continues to move up the complexity curve — combining strong compliance, first-cycle approvals, advanced drug-delivery platforms, and increasing automation. The early success of our US front end, along with investments in pre-filled syringes, BFS, and “Visual Integration” project positions us well for the next phase of growth. As we look ahead, we remain guided by a simple principle: build compliance through automation, expand capabilities ahead of demand, and grow businesses that can compound sustainably. With a strong balance sheet, a deep pipeline, and a clear strategic roadmap, we are confident in our ability to create lasting value for patients, partners, and shareholders alike.


Strategic Growth Initiatives

Project Summary

Facility	Location	Product	Target Market	Status	Timeline
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes.	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	OSD – Completed Injectable – Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity Completed.	Q3 FY27
OSD Facility	Puducherry	Oral Solid Dosages	Existing Market along with Mexico, Brazil, US and EU	Civil activity ongoing at full swing.	Q3 FY27
COL* Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmics	Existing and Regulated Markets	Civil & Structural activity ongoing at full swing.	Q4 FY27

*Caplin One Labs Limited

Caplin Point has allocated an enhanced Capex budget of approximately ₹1000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process.



Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai (CP4)
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry (CP1)
6. APIIC, Visakhapatnam

About Caplin Point Laboratories Limited:

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company also has a growing presence in the regulated markets such as US through its Subsidiary Caplin Steriles Limited and Caplin Steriles USA Inc.

Caplin Point listed on Forbes “Asia’s 200 Best Under a Billion” list for 2024. Company has appeared for the **SEVENTH** time on this list (2014, 2015, 2016, 2021, 2022, 2023 and 2024) and was awarded “The Emerging Company of 2018” by Economic Times Family Business Awards.

For further information, please contact:

G Venkatram,
General Counsel & Company Secretary
Caplin Point Laboratories

+91 44 2496 8000
investor@caplinpoint.net

Simran Malhotra / Akshay Hirani
Churchgate Partners

+91 22 6169 5988
caplinpoint@churchgatepartners.com

This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor it's directors, or any of it's subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.




EARNINGS PRESENTATION 9M FY26

Rated #1 in India for “*Most Consistent Profitable Growth across the last 10 years*”

*Second Largest wealth creator for the decade ending 2020**

February 2026 | www.caplinpoint.net

Evolution Over the Decades



Contract manufacturer



Market-led Company



Plain vanilla generic products



Introducing products that plugged marketplace gaps



Negative-working capital business



2 main geographies 10 countries
(Latin America & Francophone Africa)

Becoming a responsible pharma company



Technology and research-led marketing Company



Mix of generics, branded generics and specialty molecules and Injectables



Launch specialty niche products that Create new markets in varied therapy segments



Selective use of Credit strategy to increase market share and remain cash surplus



Extended to Regulated markets like USA with recent entry into Canada, Australia, Mexico and Brazil shortly


Diversified Product Portfolio



5,000+ Products registered and 650+ Pharmaceutical formulations



36 Therapeutic Segments



Product mix covers over 65% of WHO essential drug list




Latest focus towards complex spaces




Accounts for larger shelf share across pharmacies on account of a widening product basket


Revenue from Operations



Gross Profit




EBITDA




EBIT




PAT




Earnings Per Share




Gross Profit Margins (%)




EBITDA Margins (%)




EBIT Margins (%)




PAT Margins (%)




Revenue from Operations




Gross Profit




EBITDA




EBIT



PAT



Profit Margins



Chairman Perspectives



Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Point Laboratories said:

"Our performance in the third quarter and the first nine months of FY26 reflects far more than financial outcomes - it reflects the quiet compounding of a long-term strategy built on being different from others. We have sustained our strong margins, expanded profitability, and delivered robust cash generation, all while continuing to invest heavily in capacity, technology, people and future platforms. This balance between growth and prudence remains central to how we think about building enduring value.

In Emerging Markets, our end-to-end business model continues to create a powerful competitive moat, as we create enriching value on both sides by catering to the bottom of the pyramid. By keeping products closer to customers, expanding local presence, and broadening our portfolio through internal development and global partnerships, we are steadily deepening relevance in markets that value reliability, affordability, and long-term commitment. Our progress in Latin America, the scaling of GLP-1 products, the acceleration of our "China 2.0" strategy, and our investments in oncology and APIs reinforce our belief that resilience is built through thoughtful vertical integration and geographic diversification.

In the US and other regulated markets, Caplin Steriles continues to move up the complexity curve – combining strong compliance, first-cycle approvals, advanced drug-delivery platforms, and increasing automation. The early success of our US front end, along with investments in pre-filled syringes, BFS, and "Visual Integration" project positions us well for the next phase of growth. As we look ahead, we remain guided by a simple principle: build compliance through automation, expand capabilities ahead of demand, and grow businesses that can compound sustainably. With a strong balance sheet, a deep pipeline, and a clear strategic roadmap, we are confident in our ability to create lasting value for patients, partners, and shareholders alike."

Management Team

Dr. Sridhar Ganesan

- Managing Director



Mr. D Muralidharan

- Chief Financial Officer



01

Caplin's end-to-end business model in Central and South American markets continues to drive consistent and profitable growth for the company

02

Company has revenue pipeline arising out of new tender orders in Central American markets to the tune of \$25 million

03

Mexico Update – Company has received approvals for 25 products with a pipeline of 100+ products to be filed within the next 18 months, from CPL and CSL's internal pipeline

04

As part of Caplin's continued vision of "Keeping products closer to the Customer", Company has acquired industrial land in Mexico, aimed at setting up a manufacturing and packaging facility. Company plans to build capacities to manufacture "freight heavy" products

05

Chile Update – Company shows excellent progress with private market sales in Chile through newly established subsidiary/warehouse. Caplin already holds 125+ product licenses in Chile, with several more under review/pipeline. Chile expected to be one of Caplin's Top 5 markets within 24 months

Emerging Markets Business Highlights

Company has filed its own internally developed GLP-1 products in its Central American markets. Company plans to expand GLP-1 range of products to several markets (post patents expiry) by FY27

06

Company's "China 2.0" strategy of partnering with Companies that have ANDAs/MA's approved in US and EU gathers pace, with its first Biosimilar product filing in Central America. Company has signed partnerships with multiple Chinese companies, granting access to 80+ approved ANDAs/MAs in the US and EU

07

Company's Oncology Injectable segment in Kakkalur completes all qualifications in Jan'26, and is expected to go commercial in a few weeks. Company has acquired several ANDAs in Oncology segment from 3rd parties. These products will be submitted for site transfer to COL's site by end of 2026

08

Company's first API unit, to be used predominantly for backward integration, has completed final qualifications and has scaled up 3 critical APIs. Site will go for Regulatory certifications by end of 2026, with a target towards being backward integrated for 60% of all ANDAs in a few years

09

Civil construction completed at Oncology API site in Thervoy, near Chennai. Facility expected to be operational within 9 months and will cater to Company's budding Oncology business for Regulated and Emerging Markets

10

01

Caplin Steriles Limited (CSL) continues to show robust and profitable growth with both B2B and B2C segments contributing consistently. Current split between B2B and B2C segments is 75% & 25%

02

Company receives EU GMP renewal certification for its recently concluded audit. Company also completes Saudi FDA audit successfully in Dec'25

03

Caplin Group has acquired multiple ANDAs from 3rd party companies in order to augment its growth and expand offering in the sterile products segment in Regulated markets. Company expects all acquired products to be ready for launch in the US in 12-15 months time

04

Company currently sitting on 55 ANDAs approved in the US (including partners), and several more approvals in Canada, Mexico, South Africa, UAE, Australia etc. Company's order book remains healthy for next few Quarters

05

CSL receives its first Suspension Injectable product approval, within first cycle in the US. This is in addition to its first cycle approval for an Emulsion Injectable and Emulsion Ophthalmic product, highlighting company's excellent track record from R&D and Regulatory standpoints

Emerging Markets Business Highlights

Company expects multiple new product approvals in the form of Suspension Injectables, Injections in Plastic Vials, Ready-To-Use IV Bags in the next few months. As part of Company's original pattern of "growth through Asset Light/Outsourcing model"

06

CSL's Line 6, which is a fully automated robotic line for Pre-Filled Syringes and Cartridges, has completed qualifications. Company will file 12 Pre-Filled Syringe products in US and other Regulated markets from this line, in the next 12 months. Company will also file its first GLP-1 products

07

Project work going on at full swing for CSL's Line 7, which will be a Blow-Fill-Seal line. Company's R&D working to fast-track development of 14 products in both Unit Dose Ophthalmic and Inhalation Space, a segment with very limited competition, for Regulated markets

08

With a vision to be a highly compliant facility with the best-in-class automation in place, Company has taken on a "Visual Integration" project that will convert certain legacy equipment and processes into Automated and Real Time monitored systems. This patented project will be rolled out across all Caplin group's plants in the future

09

To accommodate the growing requirements in Capacity, Automation and Compliance, project work continues at full swing at the company's COL-II plant. This is a facility that will house 8 Sterile product lines, capable of manufacturing all the products currently being manufactured and developed at CSL

10

Research & Development Capabilities



1

Caplin has 5 dedicated R&D setups (3 – DSIR approved).

2

Continuous capex investment of over Rs. 1,017 Cr over last 8 years towards enhanced manufacturing and R&D capabilities, from internal accruals.

3

Total R&D Spends (Capex + Opex) is 14.0% of 9M FY26 PAT.

4

Caplin ranks amongst the top companies in India, for R&D spend as a percentage of Revenue on average in the past 5 years.*

5

Completed R&D for 90+ APIs to be used for backward integration in US and Emerging markets. First DMF filing targeted by end of March 2026.



345

Strength of
R&D Team

64

Filed*

55



Approved*

55+


Pipeline for 3-4 years

R&D Expense (Rs. Crore)


R&D Expense as a % of Operating Revenue




Research and Development along with conscious conversion of certain fast-selling generics into Branded Generics for better profitability




9M FY26 Operating Revenue



Revenue by Business Segment
(Emerging Markets)




Revenue by Channel
(Emerging Markets)




Caplin covers a wide spectrum of pharmaceutical formulations and therapeutic segments across 23 countries with total revenue of Rs. 2,034 Cr in FY25

Manufacturing & Outsourcing



Exports



- The products produced **inhouse**
- The products are **outsourced** from quality-conscious partners in India and China

Caplin's smart strategy of balanced manufacturing and outsourcing makes it possible to be a lean organisation as well as de-risk against cost escalations, currency fluctuations and other headwinds

Generics and Branded Generics Product Mix



Non-Steroidal Antiinflammatory
Drugs-NSAIDS



Antihelminthics/ Dewormer



Analgesic



Antibiotic and Antifungal



Antihypertensive drug



Electrolytes

Caplin Point Laboratories (BSE: 524742 | NSE: CAPLIPOINT)

Manufacturing Units:

- CP I: Puducherry
- CP X: Vishakhapatnam

Research & Development:

- CP III: Amaris Clinical CRO, Chengalpattu
- CP VI: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Hyderabad
- CP VII: TICEL Bio-Park Bioequivalent dosage forms, Taramani, Chennai
- CP VIII: API's, Intermediates and Key Starting Materials for regulated and semi – regulated markets, Perungudi, Chennai

Subsidiaries of CPL

- Caplin Point Far East Ltd
- Caplin Steriles Limited (CSL)
- Caplin One Labs Limited (COL)
- Argus Salud Pharma LLP
- Caplin Point (S) Pte Ltd

Caplin Point Far East Ltd

Subsidiaries

- Nuevos Eticos Neo Ethicals S.A. Guatemala
- Neo Ethicals S.A. Nicaragua
- Drogueria Saimed de Honduras S.A
- Caplin Point El Salvador, S.A. DE C.V.
- Neoethicals CIA. LTDA Ecuador
- Caplin Point Laboratories Colombia SAS
- Neo Ethicals Chile SpA.
- Triwin Pharma S.A DE C.V Mexico

Caplin One Labs Ltd (COL)

Manufacturing Unit:

- SIDCO, Kakkalur (Near Chennai)
- Gummidi poondi, Chennai

Caplin Steriles Ltd (India)

Manufacturing Units:

- CP IV: Gummidi poondi


Research & Development:

- Perungudi, Chennai
- Gummidi poondi
- Sunsole Solar Private Ltd (Associate of CSL)

Caplin Steriles USA Inc (US)

Distribution:

- Front-end trading arm for the sale of products in the USA



Location of Plants and Facilities

1. SIDCO, Kakkalur, Near Chennai
2. Gummidipoondi, Chennai
3. Thervoy SIPCOT, Chennai
4. Corporate Office, Chennai
5. Suthukeny, Puducherry
6. APIIC, Visakhapatnam



CP I
Puducherry



CP IV
Gummidipoondi



Corporate Office and other
R&D units:
Chennai



CP III
Chengalpattu



CP VI
Hyderabad



CP VII
Chennai

Project Summary					
Facility	Location	Product	Target Market	Status	Timeline
Caplin Plant I	CP1, Suthukeny, Puducherry	Lyophilized Injectables and Dual Chamber Syringes.	Existing Markets	Completed	Completed
API Facility upgradation	Visakhapatnam, Andhra Pradesh	General API	Existing and Regulated Markets	Completed	Completed
Oncology Facility	SIDCO, Kakkalur (Near Chennai)	OSD & Injectable phase	Existing and Regulated Markets	OSD – Completed Injectable –Completed	Completed
Oncology API Facility	Thervoy SIPCOT, Chennai	Oncology API	Existing and Regulated Markets	Civil activity completed	Q3 FY27
OSD Facility	Puducherry	Oral Solid Dosages	Existing Market along with Mexico, Brazil, US and EU	Civil activity ongoing at full swing	Q3 FY27
COL* Injectable Facility	Gummidipoondi, Chennai	Injectables and Ophthalmics	Existing and Regulated Markets	Civil & Structural activity ongoing at full swing	Q4 FY27

* Caplin One Labs Limited

Caplin Point has allocated an enhanced Capex budget of approximately Rs.1,000 + Crores for the investment projects, with around 50% nearing completion and the balance to be incurred over the next 2-3 years. The intended Capex aims to augment existing production capacities, widen the product range, and achieve backward integration for a majority of the products. The Capex will be financed solely through internal accruals, and the Company will remain net cash positive throughout the process

Core Business to show consistent growth

Caplin's core business which is focused on Latin America and Francophone Africa is expected to grow at a steady pace with industry-average margins and benchmark cashflows

US Business to Boost the Growth

Aspiration is to have exceptional compliance record and focus on niche products which continues to be in shortage in US market. Caplin believes US business to be one of its primary engines that will drive growth

Backed by Enhanced Value Chain

Backward and forward integration to help save cost, capture more market and control supply chain which is expected to boost earnings

Strong Balance Sheet

Caplin's DNA of remaining debt-free and self-sustenance is highlighted by increasing cash surplus over the years. Strong Balance sheet of Caplin acts as an anchor for our long-term vision

Expansion into Other Geographies and Widening of the Portfolio

Caplin plans to enter more regulated markets such as Canada, Australia, MENA, Russia/CIS as well as enter the bigger LATAM markets of Mexico and Brazil in the near to medium term horizon

Strong operational performance driven by key pillars of Caplin's Engines

Experienced and Visionary Board of Directors (1/2)



Mr. C.C. Paarthipan

Chairman

30+ Years of experience in the pharmaceutical industry

Spearheading the group in its multi-pronged growth approach

First Gen Entrepreneur with a focus towards bottom of the pyramid



Dr. Sridhar Ganesan

Managing Director

35+ Years experience in Pharmaceutical Industry

Previously, held leadership positions in several international assignments

The Government of India's Pharmaceutical Export Promotion Council of India has designated him as an "Honorary Expert"

Has been a Faculty in BITS



Mr. Ashok Partheeban

Vice Chairman

23+ Years experience in Pharmaceutical Industry

Oversees the entire LATAM operations since 2002 as well as other emerging markets

Spearheaded market expansion and growth initiatives in the LATAM region

Holds an Associate's Degree in OPM from Harvard Business School and a Bachelor's in Marketing from Middlesex University



Mr. Vivek Partheeban

Vice Chairman

20+ years of experience in the pharmaceutical industry

Was COO at Caplin Point Laboratories Ltd, Oversees the entire U.S/regulated market. operations

Educated at Harvard Business School and Monash University

Honorary Consul for the Republic of Guatemala in Chennai since 2018



Dr. KC John

Independent Director

35+ years of experience in sustainable development

Held leadership roles in start-ups, tech ventures, and acquisitions

Expert for Tamil Nadu Industrial Development Corporation

Doctorate in Management from Indian Institute of Management, Ahmedabad

Experienced and Visionary Board of Directors (2/2)



Dr. C K Gariyali, IAS
Independent Director

Retired IAS Officer
and holds a
Doctorate in
Women Studies

Was Principal
Secretary to the
Governor of Tamil
Nadu from 2005-
08

Was Secretary to
Hon'ble CM of Tamil
Nadu

Worked with
various International
Agencies like World
Bank etc.



Dr. R Nagendran
Independent Director

Ph.D in Ecology and
Ethology and M.SC in
Zoology

Former Expert
Member of the
National Green
Tribunal and former
Head of Department
of Environmental
Science in St. Joseph's
College, Bangalore.



Mr S Deenadayalan
Independent Director

Post Graduate degree
in Social Work from
Madras School of
Social Work and Under
Graduate degree in
Sociology from
Annamalai University

Has extensively
worked and mentors
individuals enabling
them to become
successful
professionals and more
than 30,000 municipal
school students have
been benefitted by his
idealistic model.



Mr. R. Vijayaraghavan
Independent Director

35+ years of experience
as a taxation expert with
consulting and litigation
practice across India

Advises major corporate
groups in South India on
Direct Taxes, Tax
Planning, Tax Litigations

Specializes in advising
on taxation of non-
residents, joint ventures
& collaborations, double
taxation avoidance
agreements & transfer
pricing issues.



Mrs. Susan Mathew
Independent Director

Post Graduate degree
from Union Christian
College and Graduate
of Women's Christian
College, Chennai

Served 36 years in
senior IAS positions,
including as Principal
Secretary to the
Governor

She contributed to
key policies like
private power
projects and the
Comprehensive
Transport Policy in
Tamil Nadu


Q3 FY26 Consolidated Income Statement

Particulars	Q3 FY26	Q3 FY25	YoY (%)	Q2 FY26	QoQ (%)	9M FY26	9M FY25	YoY (%)
Revenue from Operation	542.77	492.96	10.1%	534.04	1.6%	1,587.03	1,435.02	10.6%
Other Income	33.68	31.36	7.4%	30.37	10.9%	87.18	70.69	23.3%
Total Revenue	576.45	524.32	9.9%	564.41	2.1%	1,674.21	1,505.71	11.2%
Cost of Goods sold	215.14	195.35	10.1%	210.30	2.3%	620.68	569.64	9.0%
Gross Profit (Excluding Other Income)	327.63	297.61	10.1%	323.74	1.2%	966.35	865.38	11.7%
<i>Gross Profit Margin (on Rev from Operations)</i>	<i>60.4%</i>	<i>60.4%</i>		<i>60.6%</i>		<i>60.9%</i>	<i>60.3%</i>	
Employee Benefit Expenses	49.78	46.77	6.4%	47.23	5.4%	140.18	131.21	6.8%
Research and Development expenses	20.54	18.16	13.1%	21.45	(4.3)%	59.95	57.00	5.2%
Other operating expenses	67.62	70.39	(3.9)%	65.89	2.6%	209.61	198.31	5.7%
Total expenditure	137.94	135.32	1.9%	134.57	2.5%	409.74	386.52	6.0%
EBITDA	223.37	193.65	15.3%	219.54	1.7%	643.79	549.56	17.1%
<i>EBITDA Margin</i>	<i>38.7%</i>	<i>36.9%</i>		<i>38.9%</i>		<i>38.5%</i>	<i>36.5%</i>	
Depreciation and Amortisation	19.28	16.20	19.0%	18.40	4.8%	53.97	48.92	10.3%
EBIT	204.09	177.45	15.0%	201.14	1.5%	589.82	500.64	17.8%
<i>EBIT Margin</i>	<i>35.4%</i>	<i>33.8%</i>		<i>35.6%</i>		<i>35.2%</i>	<i>33.2%</i>	
Finance Cost	0.18	0.18		0.16		0.51	0.44	
<i>Share of Profit/(Loss) in associates</i>	<i>(0.02)</i>	<i>(0.01)</i>		<i>0.02</i>		<i>0.04</i>	<i>(0.09)</i>	
Profit Before Tax	203.89	177.26	15.0%	201.00	1.4%	589.35	500.11	17.8%
<i>PBT Margin</i>	<i>35.4%</i>	<i>33.8%</i>		<i>35.6%</i>		<i>35.2%</i>	<i>33.2%</i>	
Tax	38.03	37.19	2.3%	40.77	(6.7)%	112.50	104.30	7.9%
Profit after Tax	165.86	140.07	18.4%	160.23	3.5%	476.85	395.81	20.5%
<i>PAT Margin</i>	<i>28.8%</i>	<i>26.7%</i>		<i>28.4%</i>		<i>28.5%</i>	<i>26.3%</i>	

Visit Our Real Time ESG Disclosure Platform

At the core of our ethos lies a steadfast commitment to embedding environmental, social, and governance principles into our operations.

Click to access ESG Profile



Welcome

Map our ESG framework with 35+ different frameworks

Download ESG data

Access to ESG factsheet

Search for keywords

Over 12 factors and 400+ KPI



Follow us: +91 44 4000 8000 info@caplinpoint.net

CAPLIN POINT Laboratories

Home The Company Infrastructure Products Investors Sustainability Careers Contact Us

CSR Trust
CSR Activities
Policies
ESG Profile

PRCD Section A: General Disclosure

Caplin Point Providing Remedies
BRINGING SMILES
To People

<https://www.caplinpoint.net/>

Caplin Point ESG Profile Link ([Click Here](#))

ESG Commitments



Community Development

- ✓ Caplin Group's state-of-the-art hospital and diagnostic centre at Gummidi poondi, Chennai



Recycled Waste

- ✓ 60.2 MT waste recycled in 2025



Environmental & Social

- ✓ Low carbon footprint
- ✓ Women empowerment
- ✓ Investments in rural healthcare

CSR

INR 8.49 Crores

Amount spent on CSR in FY25

INR 3.56 Crores

Amount spent on CSR upto 9MFY26

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others, general economic and business conditions in India and abroad, ability to successfully implement our strategy, our research & development efforts, our growth & expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its Directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Caplin Point Laboratories Ltd.



Mr G Venkatram

investors@caplinpoint.net

**Churchgate
Investor Relations**

Simran Malhotra / Akshay Hirani

caplinpoint@churchgatepartners.com

BSE 524742

NSE CAPLIPOINT

CIN: L24231TN1990PLC019053

ISIN: INE475E01026 | **DUNS:**86-148-4556 | WWW.CAPLINPOINT.NET

©2018, Caplin Point Laboratories Limited – All Rights Reserved.

"Caplin Point" and The Caplin Point Logo are trademarks of Caplin Point Laboratories Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.

